The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2025 | Promising developments in immunotherapy for gastroesophageal cancers
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of promising gastric and gastroesophageal junction adenocarcinoma therapeutic approaches, including developments in perioperative settings, such as those evaluated in the MATTERHORN study, and immunotherapy advances in metastatic disease. Key focus areas include dual targeting strategies (HER2-PD-1, FGFR2B inhibition) and addressing checkpoint inhibitor resistance, both primary and acquired, which represents a critical unmet need for patients progressing after initial immunotherapy success. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Today I’m also chairing and giving a talk for overview of exciting new and what we’ve done already treatments for gastric and gastroesophageal junction adenocarcinoma. Of course we are starting with perioperative setting and there’s some exciting talks in what the future is for neoadjuvant and adjuvant therapy, particularly since now we have so many important data that’s coming out and reading out, including the MATTERHORN study...
Today I’m also chairing and giving a talk for overview of exciting new and what we’ve done already treatments for gastric and gastroesophageal junction adenocarcinoma. Of course we are starting with perioperative setting and there’s some exciting talks in what the future is for neoadjuvant and adjuvant therapy, particularly since now we have so many important data that’s coming out and reading out, including the MATTERHORN study. And my talk is focused on immunotherapy in metastatic disease. What are we excited about? How do we improve on our patient cures, including patients with tumor targeting together with immunotherapy, so strategies with dual HER2-PD-1 targeting or dual clotting inhibition, FGFR inhibition, and so forth. And the biggest problem we have coming is also what do we do for patients with immune checkpoint resistant tumors, either primary resistance or acquired resistance. And that’s what my lab is primarily focused on. We have patients coming to MSK from all over the world saying, great, FOLFOX nivolumab worked very well, or pembrolizumab, trastuzumab, chemo worked well. Thank you for developing these regimens, but now my disease is progressing. What else can I get? And that’s a lot of pressure to develop these regimens and the communities coming together globally, and this is the overview that I will be presenting.
Read more...
